Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geneart, a company engaged in gene synthesis and synthetic biology, has obtained a major contract from the Wellcome Trust Sanger Institute in the UK.
Subscribe to our email newsletter
Geneart will synthesize up to 600 tailor-made genes for the Wellcome Trust Sanger Institute’s research program under this contract. The genes will be used to identify mechanisms involved in defined genetic and infectious disease. The terms of the agreement were not disclosed.
The research program at the Wellcome Trust Sanger Institute uses large-scale technologies to understand the role of genes in health and disease and create lasting resources for biomedical research. The Wellcome Trust Sanger Institute is now expanding the program of research to identify novel human extracellular receptor-ligand interactions involved in genetic diseases such as cardiovascular disease and also infectious diseases.
Ralf Wagner, CEO of Geneart, said: “We are very pleased that Geneart was selected for this project by the Wellcome Trust Sanger Institute during a tendering process. This emphasizes yet again our leading position in the market for gene synthesis. Worldwide largest capacities and our broad service portfolio allow us to meet specific customer requirements, even for large-scale contracts, in the shortest periods of time.”